# Dynamic evolution of NK cells and immune remodeling mediated by CRS + HIPEC: prognostic mechanisms and therapeutic implications for malignant peritoneal mesothelioma

**Authors:** Yi-Tong Liu, Qi-Di Zhao, Xin-Li Liang, Ru Ma, Yan-Dong Su, Rui Yang, Tian Wei, He-Liang Wu, Yu-Bin Fu, Yu-Run Cui, Yang Yu, Bing Li, Yan Li

PMC · DOI: 10.1186/s12957-025-04019-2 · 2025-11-03

## TL;DR

This study explores how natural killer (NK) cells change before and after surgery for peritoneal mesothelioma and how these changes affect patient outcomes.

## Contribution

The study identifies preoperative NK cell depletion and postoperative recovery as novel prognostic factors in malignant peritoneal mesothelioma.

## Key findings

- Preoperative NK cell reduction correlates with increased surgical risks and thrombosis.
- Postoperative NK recovery is linked to KPS scores and specific cytokine levels.
- Dynamic NK cell recovery model highlights immune remodeling influenced by baseline NK levels and PCI.

## Abstract

Malignant peritoneal mesothelioma (MPM) is a highly aggressive peritoneal malignancy with a significant recurrence rate following cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). There is an urgent need to investigate novel therapeutic strategies for MPM. Natural killer (NK) cells exhibit rapid responsiveness in anti-tumor immunity; however, NK cells’ dynamic evolution and clinical significance in MPM remain unclear.

This study retrospectively enrolled 80 newly diagnosed MPM patients (preoperative group) and 64 patients who underwent CRS + HIPEC (postoperative group). The level of NK cells (CD3−CD56dimCD16+) in peripheral blood was quantified using flow cytometry. Univariate and multivariate regression analyses were performed to evaluate the association between NK cell counts and clinicopathological characteristics, intraoperative events, and prognosis. A multivariate prediction model for NK cell recovery was established.

41 patients (51.3%) exhibited decreased NK cell levels preoperatively, which were significantly associated with an increased risk of thrombosis (P = 0.023), intraoperative plasma transfusion (P = 0.004), and prolonged hospitalization duration (P = 0.023). Postoperative dynamic changes in NK cell levels were found to correlate with Karnofsky performance scale (KPS) scores (P = 0.048) and elevated levels of IL-4, IL-5, IL-6, and IL-8 (P < 0.05). Multivariate analysis revealed that the volume of intraoperative plasma transfusion was an independent correlated factor for preoperative NK cell reduction (P = 0.013), while a low KPS score was an independent predictor of postoperative NK cell decline (P = 0.048). Survival analysis indicated that a high perioperative stress score (PSS) (P = 0.015), lymph node metastasis (P = 0.015), significant intraoperative blood loss (P = 0.013), low preoperative CD8⁺ T cell levels (P = 0.001), and reduced postoperative IL-17 expression (P = 0.013) were independent adverse prognostic factors for overall survival (OS). Furthermore, the dynamic NK cell recovery model demonstrated that baseline NK cell levels, peritoneal cancer index (PCI), CD8⁺ T cell status, and postoperative recovery time all significantly influenced the immune remodeling process (all P < 0.001).

Preoperative NK depletion correlated with thrombosis and surgical risks, while postoperative NK recovery was influenced by KPS, specific cytokines (IL-4/5/6/8), and was significantly enhanced after CRS + HIPEC.

The online version contains supplementary material available at 10.1186/s12957-025-04019-2.

## Linked entities

- **Proteins:** cd.3 (Cd.3 conserved hypothetical protein), NCAM1 (neural cell adhesion molecule 1), FCGR3B (Fc gamma receptor IIIb), IL4 (interleukin 4), IL5 (interleukin 5), IL6 (interleukin 6), CXCL8 (C-X-C motif chemokine ligand 8), IL17A (interleukin 17A), CD8A (CD8 subunit alpha)
- **Diseases:** malignant peritoneal mesothelioma (MONDO:0005512), thrombosis (MONDO:0000831)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** thrombosis (MESH:D013927), lymph node metastasis (MESH:D008207), tumor (MESH:D009369), peritoneal cancer (MESH:D010534), blood loss (MESH:D016063), MPM (MESH:D000086002)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12581496/full.md

---
Source: https://tomesphere.com/paper/PMC12581496